[18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine) for Human Immunodeficiency Virus (HIV) Infection

Phase-Based Progress Estimates
Human Immunodeficiency Virus (HIV) Infection[18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine) - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is exploring the use of a new PET tracer to study HIV in the body. It will enroll people who are early or late in their infection, or who are not on treatment.

Eligible Conditions
  • Human Immunodeficiency Virus (HIV) Infection

Treatment Effectiveness

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: 1-4 hours

1-2 weeks
Correlate [18F]F-AraG uptake with measures of HIV persistence
1-4 hours
Anatomical distribution of [18F]F-AraG
[18F]F-AraG uptake in early and later-treated HIV infection

Trial Safety

Trial Design

1 Treatment Group

1 of 1

Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine) · No Placebo Group · Phase 1

Experimental Group · 1 Intervention: [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine) · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 1-4 hours

Who is running the clinical trial?

CellSight Technologies, Inc.Lead Sponsor
15 Previous Clinical Trials
267 Total Patients Enrolled
University of California, San FranciscoOTHER
2,283 Previous Clinical Trials
11,577,744 Total Patients Enrolled
National Institute of Allergy and Infectious Diseases (NIAID)NIH
3,153 Previous Clinical Trials
4,770,935 Total Patients Enrolled
Timothy J Henrich, MDPrincipal InvestigatorUniversity of California, San Francisco
1 Previous Clinical Trials
10 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: